Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Trial Profile

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium 68 satoreotide (Primary) ; Lutetium-177-DOTA-satoreotide (Primary)
  • Indications Carcinoid tumour; Colorectal cancer; Gastric cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Renal cancer
  • Focus First in man; Therapeutic Use
  • Most Recent Events

    • 22 Aug 2019 According to results published in the Clinical Cancer Research, this study was suspended when 4/7 patients unexpectedly developed G4 hematologic toxicity and restrated when second therapeutic cycle was reduced to 50 percent.
    • 22 Aug 2019 Results published in the Clinical Cancer Research
    • 25 Apr 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top